The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.
 
Jean-David Fumet
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Daiichi Sankyo Pharmaceutical; Eisai; GlaxoSmithKline; Lilly O.; MSD; Pfizer; Sandoz
Research Funding - Clovis Oncology (Inst)
 
Aurelie Bertaut
No Relationships to Disclose
 
Nicolas Roussot
No Relationships to Disclose
 
Hélène Bellio
No Relationships to Disclose
 
Leila Bengrine-Lefevre
No Relationships to Disclose
 
Julie Vincent
No Relationships to Disclose
 
Julie Niogret
No Relationships to Disclose
 
Rémi Palmier
No Relationships to Disclose
 
Thomas Collot
No Relationships to Disclose
 
Laurie Rambach
No Relationships to Disclose
 
Axelle Boudrant
No Relationships to Disclose
 
Sophie Parnalland
No Relationships to Disclose
 
Emilie Rederstorff
No Relationships to Disclose
 
Audrey Hennequin
No Relationships to Disclose
 
Sylvie Zanetta
Travel, Accommodations, Expenses - MSD Oncology
 
Alice Hervieu
Consulting or Advisory Role - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Novartis
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech